ARS Appropriate Use Criteria: Locoregionally Recurrent Rectal Cancer
TL;DRUpdated ARS appropriate use criteria for LRRC, built on 116 references (10 randomized phase 2/3), reaffirming combined-modality therapy toward R0 resection.
The RT-relevant content sits in PICO question 4 (role of RT/reirradiation), but the excerpt stops before the appropriateness ratings, so dose, fractionation and reirradiation technique recommendations are not reported in source text. What is stated: preoperative RT, systemic therapy, or both are positioned as tools to raise the odds of an R0 resection, which frames RT as resectability-directed rather than definitive.
In a previously irradiated patient with pelvic sidewall or presacral recurrence being staged for salvage, this frames preoperative RT or chemoRT as a means to margin-negative resection; it does not settle reirradiation dose or the nonoperative alternative.
RT is framed as resectability-directed: preoperative RT, systemic therapy, or both to raise the odds of R0. The reirradiation question (PICO 4) is posed but its appropriateness ratings, dose and technique are not in the source excerpt, so the decision a previously irradiated pelvis actually turns on is not reportable here.
Preoperative systemic therapy sits alongside RT as a downsizing tool rather than a competing pathway, and immunotherapy is named within the PICO question on systemic therapy. Specific regimen and sequencing ratings are not in the source excerpt.
The document is explicitly resection-centered: margin-negative resection is called the ultimate determinant of survival and local control. Resectability assessment by compartment, sidewall, sacral and visceral involvement on MRI drives the operative approach, with everything preoperative judged by whether it makes R0 more likely.
10 details 5 trials watching
Literature-based systematic review plus RAND/UCLA modified Delphi appropriateness rating, run under the standing ARS AUC methodology with PICOTS framing and PRISMA 2020 assessment. Two rounds of voting; ratings collapse to usually not appropriate, may be appropriate, usually appropriate.
Locoregionally recurrent rectal cancer. Eligible evidence was prospective observational, phase 2/3, and retrospective series of at least 25 patients, published January 1, 2013 to July 16, 2025, English language, animal studies excluded.
There is no efficacy endpoint. The output is an appropriateness rating per treatment option across five PICO questions: surgery, preoperative/perioperative therapy, nonoperative management, RT/reirradiation, and systemic therapy.
116 references carried the evidence: 10 well-designed randomized phase 2/3, 29 moderately well designed, 76 retrospective, 1 meta-analysis. The committee's stated conclusion is that margin-negative resection is the ultimate determinant of survival and local control, with preoperative systemic therapy, RT, or both used to facilitate it.
| Study design | n |
|---|---|
| Well-designed (randomized phase 2 and phase 3) | 10 |
| Moderately well designed (matched cohort, phase 2) | 29 |
| Design limitations (retrospective) | 76 |
| Meta-analysis | 1 |
Two thirds of the evidence base (76 of 116) is retrospective, so a modified Delphi vote is doing work the trials cannot. The document is an executive summary: the per-scenario appropriateness grid, which is the part a reader would carry to tumor board, is not in the source excerpt available here.
The committee explicitly declines to move practice, framing the update as reassurance about combined-modality therapy rather than a new position. For a radiation oncologist the operative question is where RT sits relative to surgical resectability, and the summary answers it in one direction only: RT is a means to R0, not an alternative to it.
- Role of nonoperative management in LRRC recruiting Radiotherapy Dose Escalation for Non-operative Management of Unresectable Locally Recurrent Rectal Cancer (STEP-UP) Phase NAn=30 · primary completion 2029-12 · RT dose escalation for unresectable LRRC, no surgery
- Optimal reirradiation dose and technique in previously irradiated pelvis recruiting Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy Phase 2n=65 · primary completion 2025-10 · dose-escalated proton reRT, prior pelvic RT >30Gy EQD2n=31 · primary completion 2025-12 · carbon ion reRT 74Gy/20Fx, unresectable LRRCrecruiting Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer Phase 2n=221 · primary completion 2030-03 · randomised 15-30Gy/5Fx reRT vs conventional RT
- Preoperative chemoRT vs systemic therapy alone before salvage resection n=44 · primary completion 2028-12 · preop chemoRT + PD-1 then radical salvage surgery
📚 Sources · 📄 1 paper
Abstract
The longer read
The most honest way to read this document is by what it declines to do. The committee says outright that its update does not suggest a major alteration of current practice, which is an unusual and useful admission in a space where guideline updates are often written to justify their own existence. Thirteen years after the 2012 ACR criteria, the central claim is unchanged: a margin-negative resection determines survival and local control, and everything else in the algorithm is instrumental to reaching one. That stability is itself the finding, and it should temper expectations that any of the intervening single-arm reirradiation and total neoadjuvant series have shifted the field's structure.
The evidence tally is where a skeptical reader should linger. Of 116 references, 76 carry design limitations and are retrospective, 29 are matched cohorts or phase 2, and only 10 are well-designed randomized phase 2 or 3 trials. A single meta-analysis rounds it out. That distribution is not a criticism of the panel so much as a description of the disease: locoregionally recurrent rectal cancer is heterogeneous by compartment involved, by prior pelvic radiation, and by interval from primary therapy, and those axes make randomization difficult and single-institution series the default. But it does mean the modified Delphi vote is carrying more inferential weight than the underlying literature can independently support. RAND/UCLA appropriateness ratings are designed for exactly this situation, and they are also the method most vulnerable to the composition of the panel. A multispecialty committee that includes colorectal surgery, surgical oncology, radiation and medical oncology, gastroenterology and radiology will produce a resection-centered consensus, and it did.
For a radiation oncologist the question that matters is whether RT is being positioned as definitive therapy for a subset or strictly as a resectability tool, and the summary text answers only the second half. Preoperative systemic therapy, radiation, or the combination are described as facilitating downsizing and improving the likelihood of a margin-negative resection. That framing subordinates RT to the surgical plan. The counterweight, nonoperative management, is one of the five PICO questions the committee posed, which implies the panel took it seriously enough to rate, but the specific ratings are not in the material available here. So is the reirradiation content, which is the single most practice-relevant piece for anyone treating a previously irradiated pelvis: cumulative dose thresholds, hyperfractionated versus conventional reirradiation schedules, and target volume in a re-treatment setting are precisely the decisions where a rated recommendation would change behavior, and none of them can be reported from this source.
What can be taken forward is the workup pathway, which is stated concretely and is not controversial: high-resolution pelvic MRI as the preferred modality, with gadolinium protocols specifically when sacral involvement or extension along sacral nerves and the lumbosacral plexus needs clarification, CT of chest, abdomen and pelvis for distant disease, and FDG-PET to separate postoperative fibrosis from active tumor. Those choices upstream determine whether a patient is offered a resection at all, and therefore whether the RT question is neoadjuvant or palliative. A reader looking for the part of this guideline that will change a Monday clinic should look there rather than at the treatment ratings, at least until the full criteria document with its per-scenario grid is in hand.